Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 18/20 | 0.98 |
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 2/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13958312 | 1.00 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL2385289 | 1.00 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| Hydrochloric Acid SCHEMBL5444462 | 0.99 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3888853 | 0.86 | ACHE (0.74) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3892442 | 0.86 | ACHE (0.74) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3894649 | 0.86 | ACHE (0.74) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13407425 | 0.85 | ACHE (0.73) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13586794 | 0.85 | ACHE (0.73) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13853640 | 0.85 | ACHE (0.75) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13853638 | 0.83 | ACHE (0.98) | ACHEMAOAMAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461388-B2 | Process for the synthesis of propargylated aminoindan derivatives | CIPLA LIMITED (IN) | 2013-06-11 | — | — | US | disclosed |
| US-8461388-B2 | Process for the synthesis of propargylated aminoindan derivatives | CIPLA LIMITED (IN) | 2013-06-11 | — | — | US | disclosed |
| US-20110054218-A1 | Process for the Synthesis of Propargylated Aminoindan Derivatives | CIPLA LIMITED (IN) | 2011-03-03 | — | — | US | disclosed |
| US-20110054218-A1 | Process for the Synthesis of Propargylated Aminoindan Derivatives | CIPLA LIMITED (IN) | 2011-03-03 | — | — | US | disclosed |
| WO-2009081148-A1 | PROCESS FOR THE SYNTHESIS OF PROPARGYLATED AMINOINDAN DERIVATIVES | CIPLA LIMITED (IN) | 2009-07-02 | — | — | WO | disclosed |
| US-7476757-B2 | Reduction of indanone in presence of hydrogenation catalyst to form indanol; reacting with propargylamine under nucleophilic replacement; drug for central nervous system disorder | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-01-13 | — | — | US | disclosed |
| US-20080200720-A1 | Reduction of indanone in presence of hydrogenation catalyst to form indanol; reacting with propargylamine under nucleophilic replacement; drug for central nervous system disorder | TEVA PHARMACEUTICAL INDUSTRIES LTD. (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200720-A1 | Reduction of indanone in presence of hydrogenation catalyst to form indanol; reacting with propargylamine under nucleophilic replacement; drug for central nervous system disorder | IDH3A, IDH3B, INMT | ACHE 23/4885MAOA 451/4885MAOB 352/4885 |
| US-20110054218-A1 | Process for the Synthesis of Propargylated Aminoindan Derivatives | DAO, DDC, HRH2 | ACHE 3232/4885MAOA 811/4885MAOB 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.